

NOV. '01 5:00PM

OPPENHEIMER OC

FAX RECEIVED

NO. 023

OPPENHEIMER

OPPENHEIMER WOLFF & DONNELLY LLP

NOV 14 2001

GROUP 1600

Brussels
Los Angeles
Minneapolis
New York
Orange County
Paris
Silicon Valley
Washington D.C.

oppenheimer.com

840 Newport Center Drive, Suite 700
Newport Beach, California 92660

949.823.6000
Fax 949.823.6100

OFFICIAL

FAX COVER LETTER

November 13, 2001

TO: Examiner R. Schwartzman
COMPANY: U.S. Patent & Trademark Office
PHONE:
FAX: 703.305.3014

FROM: Louis C. Cullman
DIRECT DIAL: 949.823.6013
E-MAIL: LCullman@oppenheimer.com
RE: Serial No. 09/001039
Filed 12/30/97
GAU: 1636

COMMENTS:

This facsimile contains confidential information intended only for the use of the addressee(s) named above and may contain information that is legally privileged. If you are not the addressee or the person responsible for delivering it to the addressee you are hereby notified that reading disseminating distributing or copying this facsimile is strictly prohibited. If you have received this facsimile by mistake please immediately notify us by telephone and return the original message to us at the address above via the Postal Service (we will reimburse postage). Thank you.

Originals: ☒ Not being sent Sent by: ☐ Post Office ☐ Messenger ☐ Air Courier ☐ E-Mail

Completed by : Trudi / 6025

You should receive 11 page(s) including this page.
If the transmission is incomplete, please call 949.823.6000 as soon as possible

CERTIFICATE OF FACSIMILE
TRANSMISSION

I hereby certify that on November 13, 2001, this paper (along with any paper referred to as being attached or enclosed) is being sent via facsimile to number 703.305.3014.

Trudi Thompson
Trudi Thompson

PATENT

Applicant: Jolly et al.

Serial No.: 09/001,039

Filed: 12/30/97

Title: METHODS FOR ADMINISTRATION OF
RECOMBINANT GENE DELIVERY
VEHICLES FOR TREATMENT OF
HEMOPHILIA AND OTHER DISORDERS

Examiner: R. Schwartzman

Group Art Unit: 1636

Atty Docket No.: 1155.005 (20263.431) #320

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

3da
24-02

AMENDMENT

Commissioner for Patents
Box Amendment
Washington, D.C. 20231

Sir:

In response to the Office Action dated June 5, 2001 (paper no. 30), Applicant responds as follows:

IN THE CLAIMS

Claims 37-56 have been allowed.

Amend claims 4 and 5 as follows:

4. (Amended) A preparation of replication defective recombinant retrovirus expressing human factor VIII protein, wherein said recombinant retrovirus is capable of infecting human cells and is resistant to degradation by human complement, wherein said recombinant retrovirus preparation has a titer of HT1080 cells of greater than 10^6 cfu/ml.

5. (Amended) A preparation of replication defective recombinant retrovirus expressing human factor VIII protein, wherein said recombinant retrovirus is capable of infecting human cells and is resistant to degradation by human complement, wherein said retrovirus preparation has a titer of HT1080 cells of greater than 10^7 cfu/ml.